MIST
Milestone Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.20
−0.72%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.3M | 1.5M | — | 1.0M | 5.0M |
| Cost of Revenue | 127.0K | 114.0K | — | — | — |
| Gross Profit | 2.2M | 1.4M | — | 1.0M | 5.0M |
| Operating Expenses | |||||
| R&D Expense | 16.4M | 18.1M | 14.4M | 31.1M | 39.8M |
| SG&A Expense | 48.6M | 17.3M | 27.7M | 31.0M | 24.8M |
| General & Admin Expense | 35.8M | 17.3M | 16.7M | 15.9M | 15.7M |
| Selling & Marketing Expense | 12.8M | — | 11.0M | 15.1M | 9.1M |
| Other Expenses | 15.8M | 28.5M | — | — | — |
| Total Operating Expenses | 80.8M | 63.9M | 42.1M | 62.1M | 64.6M |
| Cost and Expenses | 80.9M | 64.0M | 42.1M | 62.1M | 64.6M |
| Operating Income (EBIT) | (78.6M) | (62.5M) | (42.1M) | (61.1M) | (59.6M) |
| Non-Operating | |||||
| Interest Income | 5.2M | 2.9M | 4.2M | 4.0M | 1.3M |
| Interest Expense | 10.8M | 3.8M | (3.6M) | 2.6M | — |
| Net Interest Income | (5.6M) | (918.0K) | 7.7M | 1.4M | 1.3M |
| Other Non-Op Income/Expense | (5.6M) | (918.0K) | 583.0K | 1.4M | 1.3M |
| Non-Operating Income (excl Interest) | (5.2M) | (2.9M) | (4.2M) | (4.0M) | (1.3M) |
| EBT (Pre-Tax Income) | (84.2M) | (63.4M) | (41.5M) | (59.7M) | (58.4M) |
| Income Tax Expense | (182.0K) | (345.0K) | — | — | — |
| Bottom Line | |||||
| Net Income | (84.0M) | (63.1M) | (41.5M) | (59.7M) | (58.4M) |
| Earnings from Cont. Ops | (84.0M) | (63.1M) | (41.5M) | (59.7M) | (58.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (84.0M) | (63.1M) | (41.5M) | (59.7M) | (58.4M) |
| Per Share | |||||
| Basic EPS | ($0.69) | ($0.75) | ($0.67) | ($1.39) | ($1.35) |
| Diluted EPS | ($0.69) | ($0.75) | ($0.67) | ($1.39) | ($1.35) |
| Revenue Per Share | $0.02 | $0.02 | $0.00 | $0.02 | $0.12 |
| Shares | |||||
| Basic Shares Outstanding | 138.7M | 83.9M | 62.2M | 43.0M | 42.5M |
| Diluted Shares Outstanding | 138.7M | 83.9M | 62.2M | 43.0M | 42.5M |
| Profitability Metrics | |||||
| EBITDA | (73.2M) | (59.5M) | (37.8M) | (57.0M) | (58.3M) |
| D&A | 172.0K | 114.0K | 105.0K | 92.0K | 89.0K |
| EBIT | (73.4M) | (59.6M) | (37.9M) | (57.1M) | (58.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026